Background Bioresorbable scaffolds (BRS) have the potential to revolutionize the treatment
of coronary artery disease. To date, limited trial data have demonstrated favorable short-and …

Background There is paucity of data on acute performance of Fantom (REVA Medical, CA), a
second generation sirolimus‐eluting bioresorbable scaffold (BRS), in ST‐segment elevation …

Aims: before agreing for reimbursment of the Absorb (ABBOTT) Bioresorbable Vascular
Scaffold (BVS), French Health Authorities required a prospective, multicentered, controlled …

Background Previous randomized controlled trials demonstrated a higher rate of stent
thrombosis with first generation (Absorb; Abbott Vascular, USA) bioresorbable vascular …

A higher rate of bioresorbable vascular scaffold (BVS) thrombosis has been observed after
device implantation compared to implantation of permanent metallic stents in recently …

Objectives The purpose of this study was to describe the multimodal outcome 12 months
after implantation of coronary bioresorbable scaffolds (BVS) for the treatment of patients with …

Aims We aimed to investigate predictors of scaffold failure and the potential impact of an
optimized scaffold implantation technique by means of a learning curve on long‐term clinical …

Background: Safety and efficacy of bioresorbable vascular scaffolds (BRS) and the role of
postdilatation on outcome in acute coronary syndrome (ACS) patients compared with those …

Incomplete stent apposition and uncovered struts are associated with a higher risk of stent
thrombosis. No data exist on the process of neointimal coverage and late apposition status …

Bioresorbable vascular scaffold (BVS) use in clinical practice for the treatment of coronary
lesions has expanded rapidly since they became commercially available. Recently, reports …